Matches in SemOpenAlex for { <https://semopenalex.org/work/W2973229073> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2973229073 endingPage "S19" @default.
- W2973229073 startingPage "S19" @default.
- W2973229073 abstract "The prognosis of metastatic ATC is dismal and there are very limited treatment options. The thyroid is one of the most immunogenic organs in the body. PD-L1 is commonly expressed on ATC tumor cells and PD-1 in the inflammatory cells in the ATC microenvironment. However, antibodies to PD-1 as single agents have a poor record in this disease. Therefore, we designed this pilot study to add T to D and together with SBRT to augment their effects in hope to improve survival. This study evaluated the addition of T (75 mg every 4 weeks up to 4 doses) to D (1500 mg every 4 weeks). SBRT 9Gy x 3 fractions was given within the first 2 weeks of treatment to produce an “abscopal” effect. Major inclusion criteria: Metastatic ATC; ECOG PS 0-2; No prior immunotherapy; Last anti-cancer treatment > 7 days prior to starting study. Primary objective 1-year overall survival with target of ≥ 2 out of 12 patients. 12 patients were accrued. Male – 50%; Median PS 1; Median Age – 71 (49-82); Prior radiation to neck (75%); Prior chemotherapy (75%). MSI-High was noted in 2/11 subjects. BRAFV600E mutation in 3/12 subjects. There were 0 confirmed responses and only 1 subject with SD for 4 cycles or longer. Median time on treatment was 11 weeks (1-28+ weeks). MSI status did not affect treatment response. MSI-High patients were on treatment before progression for 8-14 weeks. Median overall survival was 14.5 weeks with only one person alive past 1 year. Neither the presence of a BRAF or p53 mutation appeared to affect either outcome. T/D with SBRT was not active in metastatic ATC. Future studies looking at other novel immunotherapy combinations in ATC should be evaluated. Biopsies done on study are being analyzed and will be presented." @default.
- W2973229073 created "2019-09-19" @default.
- W2973229073 creator A5005775817 @default.
- W2973229073 creator A5022849992 @default.
- W2973229073 creator A5024691456 @default.
- W2973229073 creator A5027048828 @default.
- W2973229073 creator A5034694632 @default.
- W2973229073 creator A5057443219 @default.
- W2973229073 creator A5061365371 @default.
- W2973229073 creator A5075299423 @default.
- W2973229073 creator A5075531420 @default.
- W2973229073 creator A5079162702 @default.
- W2973229073 date "2019-09-01" @default.
- W2973229073 modified "2023-10-16" @default.
- W2973229073 title "A Pilot Study of Stereotactic Body Radiotherapy (SBRT) Combined with a PD-L1 Antibody Durvalumab (D) and a CTLA-4 antibody Tremelimumab (T) To Treat Metastatic Anaplastic Thyroid Cancer (ATC)" @default.
- W2973229073 doi "https://doi.org/10.1016/j.ijrobp.2019.06.416" @default.
- W2973229073 hasPublicationYear "2019" @default.
- W2973229073 type Work @default.
- W2973229073 sameAs 2973229073 @default.
- W2973229073 citedByCount "0" @default.
- W2973229073 crossrefType "journal-article" @default.
- W2973229073 hasAuthorship W2973229073A5005775817 @default.
- W2973229073 hasAuthorship W2973229073A5022849992 @default.
- W2973229073 hasAuthorship W2973229073A5024691456 @default.
- W2973229073 hasAuthorship W2973229073A5027048828 @default.
- W2973229073 hasAuthorship W2973229073A5034694632 @default.
- W2973229073 hasAuthorship W2973229073A5057443219 @default.
- W2973229073 hasAuthorship W2973229073A5061365371 @default.
- W2973229073 hasAuthorship W2973229073A5075299423 @default.
- W2973229073 hasAuthorship W2973229073A5075531420 @default.
- W2973229073 hasAuthorship W2973229073A5079162702 @default.
- W2973229073 hasConcept C121608353 @default.
- W2973229073 hasConcept C126322002 @default.
- W2973229073 hasConcept C143998085 @default.
- W2973229073 hasConcept C2776694085 @default.
- W2973229073 hasConcept C2777701055 @default.
- W2973229073 hasConcept C2777742743 @default.
- W2973229073 hasConcept C2778650287 @default.
- W2973229073 hasConcept C2779761222 @default.
- W2973229073 hasConcept C2780030458 @default.
- W2973229073 hasConcept C2780256643 @default.
- W2973229073 hasConcept C2781274730 @default.
- W2973229073 hasConcept C2781433595 @default.
- W2973229073 hasConcept C71924100 @default.
- W2973229073 hasConceptScore W2973229073C121608353 @default.
- W2973229073 hasConceptScore W2973229073C126322002 @default.
- W2973229073 hasConceptScore W2973229073C143998085 @default.
- W2973229073 hasConceptScore W2973229073C2776694085 @default.
- W2973229073 hasConceptScore W2973229073C2777701055 @default.
- W2973229073 hasConceptScore W2973229073C2777742743 @default.
- W2973229073 hasConceptScore W2973229073C2778650287 @default.
- W2973229073 hasConceptScore W2973229073C2779761222 @default.
- W2973229073 hasConceptScore W2973229073C2780030458 @default.
- W2973229073 hasConceptScore W2973229073C2780256643 @default.
- W2973229073 hasConceptScore W2973229073C2781274730 @default.
- W2973229073 hasConceptScore W2973229073C2781433595 @default.
- W2973229073 hasConceptScore W2973229073C71924100 @default.
- W2973229073 hasIssue "1" @default.
- W2973229073 hasLocation W29732290731 @default.
- W2973229073 hasOpenAccess W2973229073 @default.
- W2973229073 hasPrimaryLocation W29732290731 @default.
- W2973229073 hasRelatedWork W2285109017 @default.
- W2973229073 hasRelatedWork W2901721165 @default.
- W2973229073 hasRelatedWork W2909918855 @default.
- W2973229073 hasRelatedWork W2973229073 @default.
- W2973229073 hasRelatedWork W3014910013 @default.
- W2973229073 hasRelatedWork W3125474097 @default.
- W2973229073 hasRelatedWork W3200440666 @default.
- W2973229073 hasRelatedWork W4213235877 @default.
- W2973229073 hasRelatedWork W4226042030 @default.
- W2973229073 hasRelatedWork W4243891274 @default.
- W2973229073 hasVolume "105" @default.
- W2973229073 isParatext "false" @default.
- W2973229073 isRetracted "false" @default.
- W2973229073 magId "2973229073" @default.
- W2973229073 workType "article" @default.